

(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 783 888 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
16.07.1997 Bulletin 1997/29(51) Int. Cl.⁶: A61K 31/425

(21) Application number: 96309418.0


(22) Date of filing: 20.12.1996

(84) Designated Contracting States:
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE• Miyamoto, Masaaki,
c/o Sankyo Company Limited
Shinagawa-ku, Tokyo 140 (JP)

(30) Priority: 26.12.1995 JP 338440/95

• Horikoshi, Hiroyoshi,
c/o Sankyo Company Limited
Shinagawa-ku, Tokyo 140 (JP)(71) Applicant: SANKYO COMPANY LIMITED
Chuo-ku, Tokyo 103 (JP)(74) Representative: Gibson, Christian John Robert
MARKS & CLERK,
57/60 Lincoln's Inn Fields
London WC2A 3LS (GB)(72) Inventors:
• Fujiwara, Toshihiko,
c/o Sankyo Company Limited
Shinagawa-ku, Tokyo 140 (JP)(54) Use of troglitazone and related thiazolidinediones in the manufacture of a medicament for
the treatment and prophylaxis of osteoporosis

(57) Compounds of formula (I):

[where R¹, R², R⁴ and R⁵ are hydrogen or alkyl and R³ is hydrogen, alkyl or various organic groups] are effective
against osteoporosis at doses at which they also effectively control diabetes.

Description

The present invention relates to a new use for a series of known thiazolidine derivatives in the treatment and prophylaxis of osteoporosis, especially in patients also suffering from diabetes or pre-diabetic or diabetic-related conditions.

Osteoporosis is frequently observed in older patients, the numbers of whom are increasing, and especially in post-menopausal women. The number of diabetic patients has also been increasing in recent years. Accordingly, the number of patients suffering both osteoporosis and diabetes has shown a considerable increase. As a result, the treatment and prophylaxis of osteoporosis, especially in diabetic patients, has recently become of increasing importance.

Although it is not known whether there is a direct causal relationship between some types of diabetes and osteoporosis, a number of mechanisms has been suggested as the cause of osteoporosis in diabetic patients, for example the following:

- an increase in calcium excretion due to hyperglycemia-induced osmotic diuresis;
- a decrease in renal calcium reabsorption due to a disorder in the vitamin D metabolism;
- a decrease in calcium absorption from the digestive tract;
- a decrease in bone metabolism due to chronically decreased magnesium and due to dysfunction of the parathyroid hormone;
- a decrease in bone formation, or deficiency of insulin action.

However, because the cause of diabetes-related osteoporosis has not yet been established, adequate methods of therapy and prevention have not been determined.

Many thiazolidine derivatives are known for the treatment and prophylaxis of diabetes. Examples of such compounds are disclosed in EP 678 511, EP 676 398, EP 590 793, EP 543 662, EP 549 366, EP 549 365, EP 708 098 and US 4 687 777. Of these, the compounds structurally closest to the compounds of the present invention are believed to be those disclosed in EP 676 398. Several of the prior art documents suggest that the compounds disclosed therein can be used for the treatment and/or prophylaxis of osteoporosis as well as of diabetes. However, a recent report [J. Bone & Mineral Research, 10(1), S361 (1995), Abstract of a paper entitled "Effects of thiazolidinediones on bone turnover in the rat" by C. Jennermann et al.] has suggested that, far from assisting in the treatment and/or prophylaxis of osteoporosis, these thiazolidine derivatives, particularly pioglitazone, one of the leading candidates for commercialisation, actually lead to bone loss, as assessed by a decrease in bone mineral density ("BMD"), thus increasing osteoporosis.


We have now found that these prior art compounds are capable of treating both osteoporosis and diabetes, although not simultaneously, since the anti-diabetic and anti-osteoporosis effects are exhibited at different dosages. Specifically, the dosages of the prior art compounds referred to above at which they are effective against osteoporosis are significantly lower than those required for the treatment of diabetes. Indeed, at the doses at which these prior art compounds are effective against diabetes, they cause a reduction in bone mineral density. At the doses at which they are effective against osteoporosis, they are ineffective, or only partially effective, against diabetes. Since, as explained above, diabetes and osteoporosis are often seen simultaneously in the same patient, the physician would have the choice of either treating the diabetes and not treating osteoporosis with these drugs (and often running the risk of aggravating the osteoporosis) or treating the osteoporosis with these drugs, but in a dose not sufficient to treat the diabetes. Effectively, this means that patients with both osteoporosis and diabetes cannot be treated for either disorder with these drugs.

However, we have now surprisingly found that a certain limited class of known thiazolidine derivatives can be used for the treatment and prophylaxis of both osteoporosis and diabetes or pre-diabetic or diabetic-related conditions, and that, with this limited class of thiazolidine derivatives, at the dose at which they are wholly effective against diabetes, they are also effective against osteoporosis.

The compounds employed in the present invention are certain of those disclosed in Japanese Patent Kokai Application Sho 60-51189, US Patent No. 4 572 912 and European Patent No. 139 421, where they have been suggested for use in the treatment and prophylaxis of diabetes, but not of osteoporosis.

We have now discovered a series of thiazolidine derivatives which are capable of being used as anti-osteoporosis and anti-diabetic drugs at the same time and in the same patient.

The invention thus provides the use of a thiazolidine compound for the manufacture of a medicament for the treatment or prophylaxis of osteoporosis, in which said thiazolidine compound is a compound of formula (I):



in which:

15 R^1 and R^2 are the same as or different from each other and each represents a hydrogen atom or an alkyl group having from 1 to 5 carbon atoms;

20 R^3 represents a hydrogen atom, an aliphatic acyl group having from 1 to 6 carbon atoms, a cycloalkanecarbonyl group having from 5 to 7 carbon atoms in the cycloalkane part, a benzoyl group, a naphthoyl group, a benzoyl or naphthoyl group which is substituted by at least one of substituents α , defined below, a heterocyclic acyl group in which the heterocyclic part has from 4 to 7 ring atoms of which from 1 to 3 are nitrogen and/or oxygen and/or sulphur hetero-atoms, a phenylacetyl group, a phenylpropionyl group, a phenylacetyl or phenylpropionyl group which is substituted by at least one halogen substituent, a cinnamoyl group, an alkoxy carbonyl group having from 1 to 6 carbon atoms in the alkoxy part or a benzyloxycarbonyl group;

25 R^4 and R^5 are the same as or different from each other and each represents a hydrogen atom, an alkyl group having from 1 to 5 carbon atoms or an alkoxy group having from 1 to 5 carbon atoms, or R^4 and R^5 together represent an alkylene dioxy group having from 1 to 4 carbon atoms;

30 n is 1, 2 or 3;

35 Y and Z are the same as or different from each other and each represents an oxygen atom or an imino group; and substituents α are selected from: alkyl groups having from 1 to 4 carbon atoms, alkoxy groups having from 1 to 4 carbon atoms, halogen atoms, hydroxy groups, amino groups, alkylamino groups having from 1 to 4 carbon atoms, dialkylamino groups having from 1 to 4 carbon atoms in each alkyl part, and nitro groups; or a pharmaceutically acceptable salt thereof.

40 In the compounds used in the present invention, where R^1 represents an alkyl group having from 1 to 5 carbon atoms, this may be a straight or branched chain alkyl group having from 1 to 5 carbon atoms, and examples include the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl and isopentyl groups, of which the methyl, ethyl, propyl, isopropyl, butyl, isobutyl and pentyl groups are preferred. Of these, those alkyl groups having from 1 to 4 carbon atoms are more preferred, and the methyl group is most preferred.

45 Where R^2 or R^5 represents an alkyl group having from 1 to 5 carbon atoms, this may be a straight or branched chain alkyl group having from 1 to 5 carbon atoms, and examples include the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, pentyl and isopentyl groups, of which the methyl, ethyl, propyl, isopropyl, butyl, isobutyl and pentyl groups are preferred. Of these, those alkyl groups having from 1 to 3 carbon atoms are more preferred, and the methyl group is most preferred.

50 Where R^3 represents an aliphatic acyl group, this may be a straight or branched chain group having from 1 to 6 carbon atoms, preferably an alkanoyl group having from 1 to 6 carbon atoms, for example a formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl or hexanoyl group, of which the formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl and hexanoyl groups are preferred. Those aliphatic acyl groups, particularly those alkanoyl groups, having from 1 to 4 carbon atoms are preferred and the acetyl group is most preferred.

55 Where R^3 represents an aromatic acyl group, this is a benzoyl or naphthoyl group in which the aromatic ring may be unsubstituted or it may be substituted by at least one of substituents α , defined above and exemplified below. Examples of such substituents α include:

alkyl groups having from 1 to 4 carbon atoms, which may be straight or branched chain groups, such as the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and t-butyl groups, of which we prefer the methyl and t-butyl

groups;

alkoxy groups having from 1 to 4 carbon atoms, which may be straight or branched chain groups, such as the methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy and t-butoxy groups, of which we prefer the methoxy group;

halogen atoms, such as the fluorine, chlorine, bromine and iodine atoms, of which we prefer the fluorine and chlorine atoms;

hydroxy groups;

amino groups;

alkylamino groups having from 1 to 4 carbon atoms, which may be straight or branched chain groups, such as the methylamino, ethylamino, propylamino, isopropylamino, butylamino, isobutylamino, sec-butylamino and t-butylamino groups, of which we prefer the methylamino group;

dialkylamino groups having from 1 to 4 carbon atoms in each alkyl part, which may be straight or branched chain groups, such as the dimethylamino, diethylamino, dipropylamino, diisopropylamino, dibutylamino, diisobutylamino, N-methyl-N-ethylamino, N-methyl-N-propylamino, N-methyl-N-isopropylamino, N-propylamino, N-ethyl-N-isopropylamino, N-ethyl-N-sec-butylamino, N-methyl-N-t-butylamino, N-ethyl-N-sec-butylamino, N-ethyl-N-t-butylamino, N-propyl-N-isopropylamino, N-propyl-N-butylamino, N-propyl-N-isobutylamino, N-propyl-N-sec-butylamino, N-propyl-N-t-butylamino, N-isopropyl-N-butylamino, N-isopropyl-N-isobutylamino, N-butyl-N-t-butylamino, N-isobutyl-N-sec-butylamino, N-isobutyl-N-t-butylamino, N-isobutyl-N-sec-butylamino, N-isobutyl-N-t-butylamino and N-sec-butyl-N-t-butylamino groups, of which we prefer the dimethylamino group; and

nitro groups.

Where R³ represents a substituted benzoyl or naphthoyl group, there is no particular restriction on the number of substituents, except such as may be imposed by the number of substitutable positions (5 in the case of benzoyl or 7 in the case of naphthoyl) and possibly by steric constraints. However, in general, we prefer from 1 to 3 substituents. Where there is more than one substituent, the substituents may be the same as or different from one another.

Examples of such substituted and unsubstituted benzoyl or naphthoyl groups include the benzoyl, 4-nitrobenzoyl, 3-fluorobenzoyl, 2-chlorobenzoyl, 3,4-dichlorobenzoyl, 4-aminobenzoyl, 3-dimethylaminobenzoyl, 2-methoxybenzoyl, 3,5-di-t-butyl-4-hydroxybenzoyl and 1- and 2- naphthoyl groups. Of these, we prefer the unsubstituted benzoyl and 1-naphthoyl groups, and most prefer the benzoyl group.

Where R³ represents a cycloalkanecarbonyl group, this has from 5 to 7 carbon atoms in the cycloalkane ring, and thus a total of from 6 to 8 carbon atoms in the whole group. Examples of such groups include the cyclopentanecarbonyl, cyclohexanecarbonyl and cycloheptanecarbonyl groups, of which the cyclohexanecarbonyl group is preferred.

Where R³ represents a heterocyclic acyl group, this is a group in which a heterocyclic group is attached to a carbonyl group. The heterocyclic part has from 4 to 7 ring atoms, more preferably 5 or 6 ring atoms, of which from 1 to 3, more preferably 1 or 2 and most preferably 1, are nitrogen and/or oxygen and/or sulphur hetero-atoms. Where there are 3 hetero-atoms in the heterocyclic group, these are preferably all nitrogen atoms or one or two are nitrogen atoms and, correspondingly, two or one are oxygen and/or sulphur atoms. The heterocyclic group is preferably aromatic. Examples of preferred heterocyclic acyl groups include the furoyl (more preferably 2-furoyl), thenoyl (more preferably 3-thenoyl), 3-pyridinecarbonyl (nicotinoyl) and 4-pyridinecarbonyl (isonicotinoyl) groups.

Where R³ represents a phenylacetyl or phenylpropionyl group which is substituted, preferably on the phenyl group, by at least one halogen substituent, the halogen substituent may be a fluorine, chlorine, bromine or iodine atom, and there may be from 1 to 5 such halogen substituents, preferably from 1 to 3 halogen substituents, and more preferably 1 halogen substituent. Examples of such groups include the p-chlorophenylacetyl, p-fluorophenylacetyl, p-bromophenylacetyl, p-iodophenylacetyl, o-chlorophenylacetyl, o-fluorophenylacetyl, o-bromophenylacetyl, o-iodophenylacetyl, m-chlorophenylacetyl, m-fluorophenylacetyl, m-bromophenylacetyl, m-iodophenylacetyl, 2,4-dichlorophenylacetyl, 2,4-difluorophenylacetyl, 2,4-dibromophenylacetyl, 2,4-diiodophenylacetyl, 3-(p-chlorophenyl)propionyl, 3-(p-fluorophenyl)propionyl, 3-(p-bromophenyl)propionyl, 3-(p-iodophenyl)propionyl, 3-(o-chlorophenyl)propionyl, 3-(o-fluorophenyl)propionyl, 3-(o-bromophenyl)propionyl, 3-(o-iodophenyl)propionyl, 3-(m-chlorophenyl)propionyl, 3-(m-fluorophenyl)propionyl, 3-(m-bromophenyl)propionyl, 3-(m-iodophenyl)propionyl, 3-(2,4-dichlorophenyl)propionyl, 3-(2,4-difluorophenyl)propionyl, 3-(2,4-dibromophenyl)propionyl and 3-(2,4-diiodophenyl) propionyl groups, of which the

p-chlorophenylacetyl group is most preferred.

Where R³ represents an alkoxy carbonyl group, this may be a straight or branched chain alkoxy carbonyl group having from 1 to 6 carbon atoms in the alkoxy part, i.e. having a total of from 2 to 7 carbon atoms, such as the methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, sec-butoxycarbonyl, t-butoxycarbonyl, pentyloxycarbonyl and hexyloxycarbonyl groups, of which we prefer those alkoxy carbonyl group having from 2 to 4 carbon atoms and most prefer the ethoxycarbonyl group.

Where R⁴ represents an alkyl group, this may be a straight or branched chain alkyl group having from 1 to 5 carbon atoms, such as the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl and pentyl groups, of which we prefer those alkyl groups having from 1 to 4 carbon atoms, more preferably a methyl or t-butyl group, and most preferably a methyl group.


Where R⁴ or R⁵ represents an alkoxy group, this may be a straight or branched chain alkoxy group having from 1 to 5 carbon atoms, such as the methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, t-butoxy and pentyloxy groups, of which we prefer those alkoxy groups having from 1 to 4 carbon atoms, more preferably a methoxy or t-butoxy group, and most preferably a methoxy group.

Where R⁴ and R⁵ together represent an alkylene dioxy group, this has from 1 to 4 carbon atoms and examples include the methylenedioxy, ethylenedioxy, propylenedioxy, trimethylenedioxy and tetramethylenedioxy groups, of which the methylenedioxy and ethylenedioxy groups are preferred.

n is 1, 2 or 3, but is preferably 1.

Y and Z are the same as or different from each other and each represents an oxygen atom or an imino group, preferably an oxygen atom; however, both are preferably oxygen atoms.

Preferred compounds of the present invention are those compounds of formula (Ia):



in which:

R¹, R², R⁴ and R⁵ are the same as or different from each other and each represents a hydrogen atom or an alkyl group having from 1 to 5 carbon atoms; and

R³ represents a hydrogen atom, an aliphatic acyl group having from 1 to 6 carbon atoms, a benzoyl group, a naphthoyl group, a benzoyl or naphthoyl group which is substituted by at least one of substituents α , defined below, or an alkoxy carbonyl group having from 1 to 6 carbon atoms in the alkoxy part; substituents α are selected from alkyl groups having from 1 to 4 carbon atoms, alkoxy groups having from 1 to 4 carbon atoms, halogen atoms, hydroxy groups, amino groups, alkylamino groups having from 1 to 4 carbon atoms, dialkylamino groups having from 1 to 4 carbon atoms in each alkyl part, and nitro groups; and pharmaceutically acceptable salts thereof.

Preferred classes of compounds of the present invention are those compounds of formula (I) or (Ia) and pharmaceutically acceptable salts thereof, in which:

(A) R¹ represents an alkyl group having from 1 to 4 carbon atoms.

(B) R² represents a hydrogen atom or an alkyl group having from 1 to 3 carbon atoms.

(C) R³ represents a hydrogen atom, an aliphatic acyl group having from 1 to 4 carbon atoms, an unsubstituted benzoyl or naphthoyl group, or an alkoxy carbonyl group having from 2 to 4 carbon atoms.

(D) R⁴ represents an alkyl group having from 1 to 4 carbon atoms.

(E) R⁵ represents a hydrogen atom or an alkyl group having from 1 to 3 carbon atoms.

In particular, of the above compounds, we prefer those compounds of formula (I) and (Ia), in which R¹ is as

defined in (A) above, R² is as defined in (B) above, R³ is as defined in (C) above, R⁴ is as defined in (D) above, and R⁵ is as defined in (E) above.

More preferred classes of compounds of the present invention are those compounds of formula (I) and (Ia) and pharmaceutically acceptable salts thereof, in which:

10 (F) R¹ represents an alkyl group having from 1 to 4 carbon atoms.

(G) R² represents a hydrogen atom or an alkyl group having from 1 to 3 carbon atoms.

15 (H) R³ represents a hydrogen atom, an acetyl group, a benzoyl group or an ethoxycarbonyl group.

(I) R⁴ represents an alkyl group having from 1 to 4 carbon atoms.

(J) R⁵ represents a hydrogen atom or an alkyl group having from 1 to 3 carbon atoms.

20 In particular, of the above compounds, we prefer those compounds of formula (I) and (Ia), in which R¹ is as defined in (F) above, R² is as defined in (G) above, R³ is as defined in (H) above, R⁴ is as defined in (I) above, and R⁵ is as defined in (J) above.

The most preferred classes of compounds of the present invention are those compounds of formula (I) and (Ia) and pharmaceutically acceptable salts thereof in which:

25 (K) R¹ represents a methyl group.

(L) R² represents a hydrogen atom or a methyl group.

30 (M) R³ represents a hydrogen atom, an acetyl group or an ethoxycarbonyl group.

(N) R⁴ represents a methyl or a t-butyl group.

35 (O) R⁵ represents a hydrogen atom or a methyl group.

In particular, of the above compounds, we prefer those compounds of formula (I) and (Ia), in which R¹ is as defined in (K) above, R² is as defined in (L) above, R³ is as defined in (M) above, R⁴ is as defined in (N) above, and R⁵ is as defined in (O) above.

40 When the compounds of the present invention contain at least one basic group in their molecules, they can thus form acid addition salts. Examples of such acid addition salts include: salts with mineral acids, especially hydrohalic acids (such as hydrofluoric acid, hydrobromic acid, hydroiodic acid or hydrochloric acid), nitric acid, perchloric acid, carbonic acid, sulphuric acid or phosphoric acid; salts with lower alkanesulphonic acids, such as methanesulphonic acid, trifluoromethanesulphonic acid or ethanesulphonic acid; salts with arylsulphonic acids, such as benzenesulphonic acid, or p-toluenesulphonic acid; salts with organic carboxylic acids, such as acetic acid, fumaric acid, tartaric acid, oxalic acid, maleic acid, malic acid, succinic acid, benzoic acid, mandelic acid, ascorbic acid, lactic acid, gluconic acid or citric acid; and salts with amino acids, such as glutamic acid or aspartic acid. Such acid addition salts may readily be prepared by conventional means.

45 The compounds of the present invention can also form salts with cations, e.g. metals. Examples of such salts include: salts with an alkali metal, such as sodium, potassium or lithium; salts with an alkaline earth metal, such as barium or calcium; salts with another metal, such as magnesium or aluminium; ammonium salts; organic base salts, such as a salt with methylamine, dimethylamine, triethylamine, diisopropylamine, cyclohexylamine or dicyclohexylamine; and salts with a basic amino acid, such as lysine or arginine. Such salts may likewise readily be prepared by conventional means.

50 The compounds of the present invention can exist in the form of various isomers.

55 Thus, the carbon atom at position 2 of the chromane ring and that at position 5 of the thiazolidine ring are both asymmetric carbon atoms. In each of the compounds of formula (I) and (Ia), stereoisomers due to these asymmetric carbon atoms as well as equimolar and non-equimolar mixtures thereof are all represented by only the one formula. Accordingly, the scope of the present invention covers all of these isomers separately, as well as all mixtures thereof.

In the compounds of formula (I) in which Y and Z both represent imino groups, in which Y and Z both represent


oxygen atoms and in which one of Y and Z represents an oxygen atom and the other represents an imino group can exist in the form of various tautomers as explained in Japanese Patent Kokai Application Sho 60-51189, US Patent No. 4 572 912 and European Patent No. 139 421.

In each of the compounds of formula (I) and (Ia), the tautomers and equimolar and non-equimolar mixtures thereof are all represented by only the one formula. Accordingly, the scope of the present invention covers all of these tautomers and all mixtures thereof.

The compounds of the present invention can also form solvates (for example hydrates), and the present invention embraces all such solvates.

The present invention covers additionally all of the so-called "pro-drugs" which can be converted by metabolic change *in vivo* into any one of the compounds of formula (I) or salts thereof.

Specific examples of the compounds of formula (I) are those compounds of formula (Ia):



25 in which R¹, R², R³, R⁴ and R⁵ are as defined in the following Table 1. In the Table, the following abbreviations are used:

Ac:	acetyl,
iBu:	isobutyl,
tBu:	t-butyl,
Byr:	butyryl,
Bz:	benzoyl,
Etc:	ethoxycarbonyl,
Et:	ethyl,
Me:	methyl,
Pn:	pentyl.

40

45

50

55

Table 1

Compound No.	R ¹	R ²	R ³	R ⁴	R ⁵
1	Me	Me	H	Me	Me
2	H	Me	H	Me	Me
3	Me	H	H	H	H
4	Me	H	H	tBu	H
5	Et	Me	H	Me	Me
6	iBu	Me	H	Me	Me
7	Pn	Me	H	Me	Me
8	Me	Me	Ac	Me	Me
9	Me	Me	Bz	Me	Me
10	Me	Me	Etc	Me	Me
11	Me	H	Ac	Me	H
12	Me	H	H	Me	H
13	Me	Me	Byr	Me	Me

Of the compounds listed above, preferred compounds are Compounds No.:

1. 5-[4-(6-Hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidin-2,4-dione;
 4. 5-[4-(6-Hydroxy-2-methyl-7-t-butylchroman-2-ylmethoxy)benzyl]thiazolidin-2,4-dione;
 5. 5-[4-(6-Hydroxy-2-ethyl-5,7,8-trimethylchroman-2-ylmethoxy)benzyl]thiazolidin-2,4-dione;
 6. 5-[4-(6-Hydroxy-2-isobutyl-5,7,8-trimethylchroman-2-ylmethoxy)benzyl]thiazolidin-2,4-dione;
 8. 5-[4-(6-Acetoxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidin-2,4-dione;
 10. 5-[4-(6-Ethoxycarbonyl-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidin-2,4-dione;
- and pharmaceutically acceptable salts thereof.

More preferred compounds are Compounds No. 1, 4 and 10, and the most preferred compound is Compound No. 1.

The compounds of the present invention are known compounds, and are described in, for example, Japanese Patent Kokai Application Sho 60-51189, US Patent No. 4572912 and European Patent No. 0139421. They may be prepared as described in these documents or by other known methods.

The thiazolidine derivatives or pharmaceutically acceptable salts thereof of the present invention can be administered by various routes. The route of administration is not particularly limited, and is determined according to the drug preparation form, and the condition of the patient, such as the age, sex and the degree of disease. For example, when tablets, pills, powders, granules, syrups, liquid preparations, suspensions, emulsions or capsules are used, these may be administered orally. When injections are used, these may be injected intravenously by themselves or in admixture with the usual fluid replacements, such as glucose and amino acids; or they may be, if necessary, be administered intramuscularly, intracutaneously, subcutaneously or intraperitoneally by themselves. When suppositories are used, these may be administered intrarectally.

The compounds of the present invention may be administered alone or in admixture with any known additives commonly used in the field of drug preparation such as vehicles, binders, disintegrators, lubricants, solubilizers, corrigents and coating agents. Such preparations may be obtained by known means.

When tablets are to be prepared, carriers which are widely known in this field can be employed, for example: vehicles such as lactose, sucrose, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, crystalline cellulose

and silicic acid; binders such as water, ethanol, propanol, simple syrup, glucose solution, starch solution, gelatine solution, carboxymethyl cellulose, purified shellac, methyl cellulose, potassium phosphate and polyvinylpyrrolidone; disintegrators such as dry starch, sodium alginate, agar powder, laminaran powder, sodium bicarbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid esters, sodium laurylsulphate, stearic acid monoglyceride, starch and lactose; disintegration inhibitors such as sucrose, stearine, cacao oil and hydrogenated oil; absorption accelerators such as quaternary ammonium bases and sodium laurylsulphate; humectants such as glycerin and starch; adsorbers such as starch, lactose, kaolin, bentonite and colloidal silicic acid; and lubricants such as purified talc, a salt of stearic acid, powdery boric acid and polyethylene glycol. In addition, the tablets can be, if necessary, prepared as ordinary coated tablets such as sugar-coated tablets, gelatine-coated tablets, enteric coated tablets, film-coated tablets, or as double-layer tablets or multi-layer tablets.

When pills are to be prepared, carriers which are widely known in this field can be employed, for example: vehicles such as glucose, lactose, starch, cacao oil, hardened vegetable oil, kaolin and talc; binders such as gum arabic, tragacanth powder, gelatine and ethanol; and disintegrators such as laminaran agar.

When suppositories are to be prepared, carriers which are widely known in this field can be employed, for example: polyethylene glycol, cacao oil, a higher alcohol, a higher alcohol ester, gelatine and semi-synthetic glyceride.

When injections are to be prepared, they may be solutions, emulsions or suspensions which are preferably sterilised and isotonic to blood. When these solutions, emulsions and suspensions are to be prepared, diluents conventionally used in this field can be employed; for example, water, ethyl alcohol, propylene glycol, ethoxy-isostearyl alcohol, polyoxy-isostearyl alcohol and a fatty acid ester of polyoxyethylene sorbitan. In this case, sufficient sodium chloride, glucose or glycerin to make the solution isotonic may be included in these preparations; or ordinary solubilizers, buffers or pain suppressers may be added.

In addition, colouring agents, preservatives, perfumes, flavors, sweetenings and any other drugs may be added, if necessary.

The amount of the active ingredient contained in these preparations is not particularly limited and may be selected over a wide range. In general, from 1 to 70% by weight, preferably from 1 to 30% by weight, of the active ingredient may be present in the whole composition.

Although the dosage may vary depending on the symptoms, age and body weight of the patient, as well as the route of administration and the form of the drug, an upper limit of 5,000 mg (preferably 1,000 mg, and more preferably 500 mg), and a lower limit of 5 mg (preferably 10 mg, and more preferably 50 mg), may be given daily to an adult human patient.

Osteoporosis may be assessed by a measurement of bone mineral density. Bone mineral density can be measured according to the method reported, for example, in Radioisotope, 37, (9), 521 - 524 (1988) or in Rinsho-Hoshisen, 35, (1), 41-48 (1990).

Alternatively, bone mineral density can be measured using the simple photon absorption method [Science, 142, 230 - 236 (1963)] or the quantitative CT method [Invest. Radiol. 12, 541 - 551 (1977)].

The efficacy of the compounds of the present invention was tested as described in the following Examples.

EXAMPLE 1

40 Measurement of bone mineral density

Three groups of animals were tested:

1. Zucker Diabetic Fatty rats ("ZDF rats"): these are experimental animals with spontaneous diabetes mellitus. A test drug was administered to these animals in a conventional F2 powdery feed. This group is referred to as the "test ZDF group".

2. ZDF rats to which the F2 powdery feed is administered without the drug. This group is referred to as the "control ZDF group".

3. Normal experimental rats (i.e. not ZDF rats) to which the F2 powdery feed is administered without the drug. This group is referred to as the "normal group".

Compound No. 1, or 5-[4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidin-2,4-dione, also known as "troglitazone", was administered to 6 week old ZDF rats, by mixing it into F2 powdery feed in an amount of 0.2% w/w for a period of 13 weeks. The mean dosage was 165 mg/kg/day. At this dose, diabetes is fully controlled. At 19 weeks of age, the rats were sacrificed by ether anesthesia followed by blood-letting from the abdominal aorta. The femoral bones were excised to measure their bone mineral density. For the measurement by X ray, Bone Mineral Density Measuring Apparatus (DCS-600R, Aloka, Japan) was employed.

5 The results are shown in Table 2.

Table 2

Bone mineral density (mg/cm ²)		
	Number of rats in group	BMD
Normal group	7	187.3 ± 2.3***
Control ZDF group	7	164.6 ± 3.9
Test ZDF group	7	172.8 ± 7.2*

10 1) The values of the bone mineral density are given by the mean value ± standard error.
 15 2) * and *** indicate significant differences from the value of control ZDF rats at p<0.05 and p<0.001 respectively.

20 As is clearly shown in Table 2, the thiazolidine derivatives of the present invention and pharmaceutically acceptable salts thereof showed an excellent improvement on the bone mineral density.

EXAMPLE 2

Comparison of effects of troglitazone and pioglitazone on bone mineral density

25 The experiment reported in Example 1 was repeated, using 4 groups of rats:

- 30 1. A normal group (as in Example 1).
2. A control ZDF group (as in Example 1).
3. A test ZDF group in which troglitazone was present in the feed in an amount of 0.2%, resulting in an average uptake of 132 mg/kg/day (hereinafter the "troglitazone ZDF group").
- 35 4. A test ZDF group in which pioglitazone was present in the feed in an amount of 0.067%, resulting in an average uptake of 52.6 mg/kg/day (hereinafter the "pioglitazone ZDF group").

40 Pioglitazone is more active than troglitazone and so less is needed to achieve an anti-diabetic effect. At the doses used, both pioglitazone and troglitazone fully controlled diabetes in the ZDF rats.

The results are shown in Table 3.

Table 3

Bone mineral density (mg/cm ²)		
	Number of rats in group	BMD
Normal group	6	187.4 ± 1.5
Control ZDF group	6	157.0 ± 2.2
Troglitazone ZDF group	6	169.4 ± 1.1***
Pioglitazone ZDF group	6	149.3 ± 1.8*

45 50 55 1) The values of the bone mineral density are given by the mean value ± standard error.
 2) * and *** indicate significant differences from the value of control ZDF rats at p<0.05 and p<0.001 respectively.

From these results it can be seen that the compound of the present invention (troglitazone) increased BMD from the depressed level in the control ZDF rats almost to the level found in normal rats. In contrast, pioglitazone reduced BMD to below the level found in untreated ZDF rats, thus indicating that it would have the unfortunate side effect of initiating or enhancing osteoporosis in diabetic mammals.

5

EXAMPLE 3

Comparison of effects of troglitazone and pioglitazone on bone density

10 The experiment reported in Example 1 was repeated, but only for 4 weeks, using 6 groups of rats:

1. A normal group (as in Example 1).
2. A control ZDF group (as in Example 1).
- 15 3. A test ZDF group in which troglitazone was present in the feed in an amount of 0.05%, resulting in an average uptake of 43.5 mg/kg/day (hereinafter the "low troglitazone ZDF group").
4. A test ZDF group in which troglitazone was present in the feed in an amount of 0.1%, resulting in an average uptake of 89.8 mg/kg/day (hereinafter the "high troglitazone ZDF group").
- 20 5. A test ZDF group in which pioglitazone was present in the feed in an amount of 0.0125%, resulting in an average uptake of 12.4 mg/kg/day (hereinafter the "low pioglitazone ZDF group").
6. A test ZDF group in which pioglitazone was present in the feed in an amount of 0.025%, resulting in an average uptake of 23.1 mg/kg/day (hereinafter the "high pioglitazone ZDF group").

25 At these doses, troglitazone and pioglitazone do not control diabetes or control it only partially.

The results are shown in Table 4.

30

Table 4

Bone mineral density (mg/cm ²)		
	Number of rats in group	BMD
Normal group	10	153.4 ± 0.9
Control ZDF group	5	149.8 ± 1.0
Low troglitazone ZDF group	5	156.6 ± 1.5***
High troglitazone ZDF group	5	159.8 ± 1.2***
Low pioglitazone ZDF group	5	151.2 ± 0.9
High pioglitazone ZDF group	5	151.2 ± 0.7
1) The values of the bone mineral density are given by the mean value ± standard error.		
2) *** indicates a significant difference from the value of control ZDF rats at p<0.001.		

50

From these results it can be seen that only troglitazone improves BMD as compared with the control ZDF group, while pioglitazone is not effective. However, at these doses, both troglitazone and pioglitazone are incompletely effective against diabetes.

55

EXAMPLE 4Acute toxicity

5 The acute toxicity of troglitazone was examined by a conventional procedure.
To 3 ddY-mice, a dose of 300 mg/kg of troglitazone was administered orally. After 5 days, all mice were alive.

The acute toxicities of Compounds Nos. 2, 3, 4 and 10 were examined in a similar way by oral administration. The acute toxicity values were all found to be more than 300 mg/kg.

PREPARATIONCapsule preparation

15 The following ingredients were filled in a gelatine capsule:


Compound No. 1	100 mg
Lactose	168.3 mg
Corn starch	70 mg
Magnesium stearate	1.7 mg
Total	340 mg

20

25

Claims

- 30 1. The use of a thiazolidine compound in the manufacture of a medicament for treating or preventing osteoporosis, said thiazolidine compound being a compound of formula (I):



35

40

45

in which:

R¹ and R² are the same as or different from each other and each represents a hydrogen atom or an alkyl group having from 1 to 5 carbon atoms;

50 R³ represents a hydrogen atom, an aliphatic acyl group having from 1 to 6 carbon atoms, a cycloalkanecarbonyl group having from 5 to 7 carbon atoms in the cycloalkane part, a benzoyl group, a naphthoyl group, a benzoyl group in which the heterocyclic part has from 4 to 7 ring atoms of which from 1 to 3 are nitrogen and/or oxygen and/or sulphur hetero-atoms, a phenylacetyl group, a phenylpropionyl group, a phenylacetyl or phenylpropionyl group which is substituted by at least one halogen substituent, a cinnamoyl group, an alkoxy carbonyl group having from 1 to 6 carbon atoms in the alkoxy part or a benzyloxycarbonyl group;

55 R⁴ and R⁵ are the same as or different from each other and each represents a hydrogen atom, an alkyl group having from 1 to 5 carbon atoms or an alkoxy group having from 1 to 5 carbon atoms, or R⁴ and R⁵ together


represent an alkyleneoxy group having from 1 to 4 carbon atoms;

n is 1, 2 or 3;

Y and Z are the same as or different from each other and each represents an oxygen atom or an imino group; and

substituents α are selected from alkyl groups having from 1 to 4 carbon atoms, alkoxy groups having from 1 to 4 carbon atoms, halogen atoms, hydroxy groups, amino groups, alkylamino groups having from 1 to 4 carbon atoms, dialkylamino groups having from 1 to 4 carbon atoms in each alkyl part, and nitro groups; and pharmaceutically acceptable salts thereof.

2. A use according to Claim 1, in which said thiazolidine compound has the formula (Ia):



in which R¹, R², R³, R⁴ and R⁵ are as defined in Claim 1.

3. A use according to Claim 1 or Claim 2, in which R¹ represents an alkyl group having from 1 to 4 carbon atoms.

4. A use according to Claim 1 or Claim 2, in which R² represents a hydrogen atom or an alkyl group having from 1 to 3 carbon atoms.

5. A use according to Claim 1 or Claim 2, in which R³ represents a hydrogen atom, an aliphatic acyl group having from 1 to 4 carbon atoms, an unsubstituted benzoyl or naphthoyl group or an alkoxy carbonyl group having from 2 to 4 carbon atoms.

6. A use according to Claim 1 or Claim 2, in which R⁴ represents an alkyl group having from 1 to 4 carbon atoms.

7. A use according to Claim 1 or Claim 2, in which R⁵ represents a hydrogen atom or an alkyl group having from 1 to 3 carbon atoms.

8. A use according to Claim 1 or Claim 2, in which:

R¹ represents an alkyl group having from 1 to 4 carbon atoms;

R² represents a hydrogen atom or an alkyl group having from 1 to 3 carbon atoms;

R³ represents a hydrogen atom, an aliphatic acyl group having from 1 to 4 carbon atoms, an unsubstituted benzoyl or naphthoyl group, or an alkoxy carbonyl group having from 2 to 4 carbon atoms;

R⁴ represents an alkyl group having from 1 to 4 carbon atoms; and

R⁵ represents a hydrogen atom or an alkyl group having from 1 to 3 carbon atoms.

9. A use according to Claim 1 or Claim 2, in which R³ represents a hydrogen atom, an acetyl group, a benzoyl group or an ethoxycarbonyl group.

10. A use according to Claim 1 or Claim 2, in which:

EP 0 783 888 A1

5 R¹ represents an alkyl group having from 1 to 4 carbon atoms;

R² represents a hydrogen atom or an alkyl group having from 1 to 3 carbon atoms;

10 R³ represents a hydrogen atom, an acetyl group, a benzoyl group or an ethoxycarbonyl group;

R⁴ represents an alkyl group having from 1 to 4 carbon atoms; and

15 R⁵ represents a hydrogen atom or an alkyl group having from 1 to 3 carbon atoms.

11. A use according to Claim 1 or Claim 2, in which R¹ represents a methyl group.

12. A use according to Claim 1 or Claim 2, in which R² represents a hydrogen atom or a methyl group.

15 13. A use according to Claim 1 or Claim 2, in which R³ represents a hydrogen atom, an acetyl group or an ethoxycarbonyl group.

14. A use according to Claim 1 or Claim 2, in which R⁴ represents a methyl or a t-butyl group.

20 15. A use according to Claim 1 or Claim 2, in which R⁵ represents a hydrogen atom or a methyl group.

16. A use according to Claim 1 or Claim 2, in which:

25 R¹ represents a methyl group;

R² represents a hydrogen atom or a methyl group;

30 R³ represents a hydrogen atom, an acetyl group or an ethoxycarbonyl group;

R⁴ represents a methyl or a t-butyl group; and

35 R⁵ represents a hydrogen atom or a methyl group.

17. A use according to Claim 1, in which Y represents an oxygen atom.

35 18. A use according to Claim 1, in which Z represents an oxygen atom.

19. A use according to Claim 1, in which Y and Z both represent oxygen atoms.

40 20. A use according to Claim 1, in which n is 1.

21. A use according to Claim 1 or Claim 2, in which said thiazolidine compound is at least one of:

45 5-[4-(6-Hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidin-2,4-dione;

5-[4-(6-Hydroxy-2-methyl-7-t-butylchroman-2-ylmethoxy)benzyl]thiazolidin-2,4-dione;

5-[4-(6-Hydroxy-2-ethyl-5,7,8-trimethylchroman-2-ylmethoxy)benzyl]thiazolidin-2,4-dione;

50 5-[4-(6-Hydroxy-2-isobutyl-5,7,8-trimethylchroman-2-ylmethoxy)benzyl]thiazolidin-2,4-dione;

5-[4-(6-Acetoxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidin-2,4-dione;

55 5-[4-(6-Ethoxycarbonyl-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidin-2,4-dione; and pharmaceutically acceptable salts thereof.

22. A use according to any one of the preceding Claims for the manufacture of a medicament for treating or preventing osteoporosis in patients suffering from diabetes.

23. A use according to Claim 22, in which said diabetes is non-insulin dependent diabetes.

5

10

15

20

25

30

35

40

45

50

55



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 96 30 9418

DOCUMENTS CONSIDERED TO BE RELEVANT									
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.)						
D, Y	EP 0 676 398 A (SANKYO CO) 11 October 1995 * p.130, 1.49; claims * ---	1-23	A61K31/425						
D, Y	EP 0 549 365 A (SANKYO CO) 30 June 1993 * p.22, 1.13-14; claims * ---	1-23							
D, Y	J OF BONE AND MINERAL RESEARCH, vol. 10, no. S1, 1995, page s241 XP002030319 JENNERMANN ET AL: "Effects of thiazolidinediones on bone turnover in the rat" * S361 *	1-23							
			TECHNICAL FIELDS SEARCHED (Int.Cl.)						
			A61K						
<p>The present search report has been drawn up for all claims</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 33%;">Place of search</td> <td style="width: 33%;">Date of completion of the search</td> <td style="width: 34%;">Examiner</td> </tr> <tr> <td>MUNICH</td> <td>30 April 1997</td> <td>Uiber, P</td> </tr> </table>				Place of search	Date of completion of the search	Examiner	MUNICH	30 April 1997	Uiber, P
Place of search	Date of completion of the search	Examiner							
MUNICH	30 April 1997	Uiber, P							
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document							